Figure 2
From: TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays
Kaplan-Meier plots of relapse-free survival by IHC4 risk classification (A) and TP53 mutational status (B) in NTUH cohort and breast cancer-specific survival by PAM50 classification (C) and TP53 mutational status (D) in METABRIC cohort. (unadjusted analysis).
